Trial Profile

Scemblix (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asciminib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms ASSURE-3
Sponsors Novartis Pharmaceuticals

Most Recent Events

09 Apr 2024 Planned End Date changed from 15 Oct 2026 to 15 Dec 2026.
09 Apr 2024 Planned primary completion date changed from 15 Oct 2026 to 15 Dec 2026.
09 Apr 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com